Clinical trials: Newly Diagnosed Glioblastoma
Brain Tumor, Central Nervous System Tumor
Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006024
- Testing
- lomustine, temozolomide
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 32 people
- Sponsor
- Children's Oncology Group
Thrombocytopenia, Glioblastoma
Prevention of Thrombocytopenia in Glioblastoma Patients
Chemotherapy used in the treatment of primitive tumors of the central nervous system has a particularly important platelet toxicity compared to chemotherapy used for treatment of other tumors.
- Trial name
- PLATUM (NCT02227576)
- Testing
- Romiplostim
- Where
- 4 sites in France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Lille
Glioblastoma Multiforme (GBM)
PriCoTTF Study: TTFields Before and During Radiotherapy for Newly Diagnosed Glioblastoma
The PriCoTTF clinical trial is related to the development and validation of the investigational product Optune®, a device for generating tumor therapy fields (TTFields) that is used in combination with radiation therapy to treat…
- Trial name
- PriCoTTF (NCT07120620)
- Testing
- TTFields before and during radiotherapy
- Where
- Germany
- Volunteers
- 33 people
- Sponsor
- Sied Kebir
Glioblastoma, Adult
NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma
This study is a prospective single arm trial designed to study the safety, feasibility and preliminary efficacy of a medical device, NovoTTF-200A used concomitantly with standard adjuvant treatment for newly diagnosed…
- Trial name
- NCT03232424
- Testing
- NovoTTF-200A, Temozolomide, 3D conformal or intensity modulated radiation therapy (IMRT)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Hackensack Meridian Health
Anaplastic Oligoastrocytoma, Anaplastic Astrocytoma
A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas
This study is being conducted to help determine whether the addition of Interferon-alpha(α-IFN),which were determined sensitized the activity of Temozolomide(TMZ) in vivo and vitro, when given along with temozolomide during the…
- Conditions
- Anaplastic Oligoastrocytoma, Anaplastic Astrocytoma, Glioblastoma
- Trial name
- NCT01765088
- Testing
- Temozolomide, α-IFN
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
Glioblastoma
Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea
This clinical study was planned in order to assess the superiority of INNOCELL Corp. "Immuncell-LC" in aspects of therapeutic efficacy and safety when administered with Temozolomide to glioblastoma patients when compared with the…
- Trial name
- NCT00807027
- Testing
- Activated T lymphocyte(Immuncell-LC)
- Where
- 7 sites in South Korea
- Volunteers
- 180 people
- Sponsor
- GC Cell Corporation
Brain and Central Nervous System Tumors
Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for some types of brain tumors.
- Trial name
- NCT00004017
- Testing
- conventional surgery, iodine I 131 monoclonal antibody TNT-1/B
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Peregrine Pharmaceuticals
Glioblastoma
Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Open-label, randomized, controlled, phase 3 safety and efficacy registration trial. Subjects will be randomized at baseline to the standard of care for first-line treatment of glioblastoma plus Trans Sodium Crocetinate (TSC) or…
- Trial name
- INTACT (NCT03393000)
- Testing
- Trans Sodium Crocetinate plus SOC, Standard of Care (SOC)
- Where
- 13 sites in United States
- Volunteers
- 19 people
- Sponsor
- Diffusion Pharmaceuticals Inc
Glioma, Glioblastoma
Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile®
This is a phase 2, open-label clinical trial determining feasibility, safety, and tolerability of GammaTile® in elderly or frail subjects with newly diagnosed or recurrent malignant gliomas.
- Conditions
- Glioma, Glioblastoma, GBM, Glioma, Malignant
- Trial name
- ENDURANCE (NCT07821112)
- Testing
- GammaTile®
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, Irvine
Glioblastoma, Newly Diagnosed Glioblastoma
Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma
The purpose of this study is to determine the safety and efficacy of the combination therapy of TTFields + SRS+ Temozolomide (TMZ) for newly diagnosed glioblastoma (GBM).
- Trial name
- NCT04474353
- Testing
- Optune, Gadolinium, Temozolomide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University
Glioblastoma
Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma
This study will investigate whether or not intensified radiation therapy adapted during the radiation treatment course to high-risk, treatment-resistant tumor regions will improve overall survival in patients with newly diagnosed…
- Trial name
- NCT04574856
- Testing
- Dose-Intensified Radiotherapy, Temozolomide, Adjuvant temozolomide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Michigan Rogel Cancer Center
Glioblastoma Multiforme
TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.
The goal of this clinical trial is To investigate the safety and efficacy of Tumor-Treating Fields (TTFields) in combined with temozolomide (TMZ) and tislelizumab in the treatment of newly diagnosed glioblastoma (GBM).
- Trial name
- NCT06353360
- Testing
- Tumor Treating Fields, Tislelizumab, Temozolomide (TMZ)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Glioma, Glioblastoma
Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
The purpose of this Phase 2, open-label, single-arm study is to determine the safety and the maximal tolerated dose (MTD) of VAL-083 in combination with a standard of care radiation regimen when used to treat newly diagnosed GBM…
- Conditions
- Glioma, Glioblastoma, Glioblastoma Multiforme, GBM
- Trial name
- NCT03050736
- Testing
- VAL-083 (Dianhydrogalactitol)
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Kintara Therapeutics, Inc.
Glioblastoma (GBM), Newly Diagnosed Glioblastoma
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting.
- Conditions
- Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM)
- Trial name
- NCT07326566
- Testing
- silevertinib in combination with temozolomide, temozolomide (TMZ)
- Where
- 38 sites in United States
- Volunteers
- 162 people
- Sponsor
- Black Diamond Therapeutics, Inc.
Glioblastoma
RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.
In prior trials of CMV RNA-pulsed dendritic cell vaccines, there has been a narrow window between surgery and initiation of chemoradiation to enroll patients and perform leukapheresis (to obtain cells needed to generate…
- Trial name
- NCT04963413
- Testing
- Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Glioblastoma
GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
The primary objective of this study is to assess the safety and tolerability, feasibility and biological activity (immunogenicity) of the actively personalized vaccination (APVAC) concept in newly diagnosed glioblastoma (GB)…
- Trial name
- NCT02149225
- Testing
- APVAC1 vaccine plus Poly-ICLC and GM-CSF, APVAC2 vaccine plus Poly-ICLC and GM-CSF
- Where
- 6 sites in Denmark, Germany and 3 more
- Volunteers
- 16 people
- Sponsor
- Immatics Biotechnologies GmbH
Glioblastoma, Melanoma Stage IV
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors.
- Conditions
- Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer
- Trial name
- NCT04478279
- Testing
- ST101, Temozolomide, Radiation
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 125 people
- Sponsor
- Sapience Therapeutics
Glioblastoma Multiforme of Brain
Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme
This is a safety and tolerability study looking at the addition of avelumab, an immune checkpoint inhibitor, to standard therapy of temozolomide and radiotherapy in patients with newly diagnosed glioblastoma multiforme.
- Trial name
- SEJ (NCT03047473)
- Testing
- avelumab
- Where
- Canada
- Volunteers
- 38 people
- Sponsor
- Clinique Neuro-Outaouais
Glioblastoma Multiforme
Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM
This study aims to investigate effect of Nivolumab and Temozolomide vs Temozolomide alone on overall survival in newly diagnosed elderly patients with glioblastoma.
- Trial name
- NUTMEG (NCT04195139)
- Testing
- Nivolumab, Temozolomide
- Where
- 20 sites in United States, Australia
- Volunteers
- 103 people
- Sponsor
- University of Sydney
Glioma, Malignant
GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas
The purpose of this phase I trial is to test the safety of combining GMCI, an immunostimulator, plus nivolumab, an immune checkpoint inhibitor (ICI), with standard of care radiation therapy, and temozolomide in treating patients…
- Trial name
- GMCI (NCT03576612)
- Testing
- AdV-tk, Valacyclovir, Radiation
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- Candel Therapeutics, Inc.